ArticleAnnals of the rheumatic diseases2018
Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.
Article in Annals of the rheumatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study.Clinical rheumatology · 2024Pooled it
- Pooled it
- Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.European heart journal. Cardiovascular pharmacotherapy · 2020Guideline
- Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.Clinical rheumatology · 2023Trial
- Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis.Annals of the rheumatic diseases · 2023Trial
- Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis.Annals of the rheumatic diseases · 2020Trial
- Cardiovascular Risks in Autoimmune and Inflammatory Diseases.Journal of clinical medicine · 2026Article
- Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases.Rheumatology (Oxford, England) · 2026Article
- Article
- Sex-specific traditional and disease-related risk factors for incident heart failure in patients with rheumatoid arthritis: a registry-based cohort study.Clinical rheumatology · 2026Article
- Glucagon-like Peptide-1 Receptor Agonists in Rheumatoid Arthritis: A Scoping Review of Metabolic, Anti-Inflammatory, and Cardioprotective Effects.Journal of personalized medicine · 2026Review
- Cognitive impairment risk in patients with rheumatoid arthritis: a population-based cohort study.RMD open · 2026Article
- Inferring Rheumatoid Arthritis Disease Activity Status From the Electronic Health Records Across Health Systems.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Article
- Observational
- Patterns and risk of cardiovascular disease in rheumatoid arthritis and psoriatic arthritis: a nationwide cohort study in the UK.Rheumatology advances in practice · 2026Article
- Underestimation of cardiovascular risk by QRISK3 and RA-adapted SCORE2 in a Chinese rheumatoid arthritis population.Frontiers in cardiovascular medicine · 2026Article
- Rheumatoid arthritis and cardiovascular disease in relation to cytomegalovirus infection: a pilot cross-sectional study.Frontiers in medicine · 2026Article
- Reduced circulating anti-CXCR3 antibodies as a common hallmark bridging systemic autoimmunity and atherosclerosis.Frontiers in immunology · 2026Article
- Cardiovascular risk stratification in inflammatory-driven conditions: how far have we come?Frontiers in cardiovascular medicine · 2026Review
85 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
29 authors.
Funding
Abstract
objectivesPatients with rheumatoid arthritis (RA) have an excess risk of cardiovascular disease (CVD). We aimed to assess the impact of CVD risk factors, including potential sex differences, and RA-specific variables on CVD outcome in a large, international cohort of patients with RA.
methodsIn 13 rheumatology centres, data on CVD risk factors and RA characteristics were collected at baseline. CVD outcomes (myocardial infarction, angina, revascularisation, stroke, peripheral vascular disease and CVD death) were collected using standardised definitions.
results5638 patients with RA and no prior CVD were included (mean age: 55.3 (SD: 14.0) years, 76% women). During mean follow-up of 5.8 (SD: 4.4) years, 148 men and 241 women developed a CVD event (10-year cumulative incidence 20.9% and 11.1%, respectively). Men had a higher burden of CVD risk factors, including increased blood pressure, higher total cholesterol and smoking prevalence than women (all p<0.001). Among the traditional CVD risk factors, smoking and hypertension had the highest population attributable risk (PAR) overall and among both sexes, followed by total cholesterol. The PAR for Disease Activity Score and for seropositivity were comparable in magnitude to the PAR for lipids. A total of 70% of CVD events were attributable to all CVD risk factors and RA characteristics combined (separately 49% CVD risk factors and 30% RA characteristics).
conclusionsIn a large, international cohort of patients with RA, 30% of CVD events were attributable to RA characteristics. This finding indicates that RA characteristics play an important role in efforts to reduce CVD risk among patients with RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.